HAART and changes of epidemiology, treatment and prognosis of HIV-positive patients with Kaposi's sarcoma and lymphoma

被引：0
作者：
Gabarre, J
Bossi, P
机构：
[1] Hop La Pitie Salpetriere, Serv Hematol Clin, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, Serv Malad Infect & Trop, F-75013 Paris, France
来源：
BULLETIN DU CANCER | 2003年 / 90卷 / 05期
关键词：
HIV; HAART;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Highly active antiretroviral therapy (HAART) has changed the epidemiology of Kaposi's sarcoma (KS) and lymphoma occurring in people living with HIV The KS's decrease was observed early after HAART availability; although delayed, the decrease of non-Hodgkin's lymphoma has been significant. The improvement of immune status due to HAART has decreased the occurrence of chemotherapy triggered opportunistic infections, and survival rates have been improved. The administration of chemotherapy with HAART does not seem to increase toxiciy.
引用
收藏
页码：419 / 425
页数：7
相关论文
共 53 条
  • [21] Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination antiretroviral therapy
    Grulich, AE
    Li, YM
    McDonald, AM
    Correll, PK
    Law, MG
    Kaldor, JM
    [J]. AIDS, 2001, 15 (05) : 629 - 633
  • [22] Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
    Gulick, RM
    Mellors, JW
    Havlir, D
    Eron, JJ
    Gonzalez, C
    McMahon, D
    Richman, DD
    Valentine, FT
    Jonas, L
    Meibohm, A
    Emini, EA
    Chodakewitz, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) : 734 - 739
  • [23] A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
    Hammer, SM
    Squires, KE
    Hughes, MD
    Grimes, JM
    Demeter, LM
    Currier, JS
    Eron, JJ
    Feinberg, JE
    Balfour, HH
    Dayton, LR
    Chodakewitz, JA
    Fischl, MA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) : 725 - 733
  • [24] Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery
    Hoffmann, C
    Tabrizian, S
    Wolf, E
    Eggers, C
    Stoehr, A
    Plettenberg, A
    Buhk, T
    Stellbrink, HJ
    Horst, HA
    Jäger, H
    Rosenkranz, T
    [J]. AIDS, 2001, 15 (16) : 2119 - 2127
  • [25] Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy
    Holkova, B
    Takeshita, K
    Cheng, DM
    Volm, M
    Wasserheit, C
    Demopoulos, R
    Chanan-Khan, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) : 3848 - 3851
  • [26] The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic
    Ives, NJ
    Gazzard, BG
    Easterbrook, PJ
    [J]. JOURNAL OF INFECTION, 2001, 42 (02) : 134 - 139
  • [27] Jacobson LP, 1999, J ACQ IMMUN DEF SYND, V21, pS34
  • [28] Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS
    Jacomet, C
    Girard, PM
    Lebrette, MG
    Farese, VL
    Monfort, L
    Rozenbaum, W
    [J]. AIDS, 1997, 11 (14) : 1725 - 1730
  • [29] Jones JL, 1999, J ACQ IMMUN DEF SYND, V21, pS11
  • [30] Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
    Kaplan, LD
    Straus, DJ
    Testa, MA
    VonRoenn, J
    Dezube, BJ
    Cooley, TP
    Herndier, B
    Northfelt, DW
    Huang, J
    Tulpule, A
    Levine, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) : 1641 - 1648
123456